Please use this identifier to cite or link to this item: http://hdl.handle.net/10316/48375
Title: In silico studies targeting G-protein coupled receptors for drug research against Parkinson’s disease
Authors: Lemos, Agostinho 
Meloc, Rita 
Preto, Antonio J. 
Almeida, Jose G. 
Moreira, Irina S. 
Cordeiro, M. Natalia D. S. 
Keywords: Parkinson; GPCR; Computational modeling
Issue Date: 2018
Publisher: Benthan
Keywords: Parkinson; GPCR; Computational modeling
Issue Date: 2018
Publisher: Benthan
Project: info:eu-repo/grantAgreement/FCT/5876/147218/PT 
POCI/01/0145/FEDER/007265 
IF/00578/2014 
MEMBRANEPROT 659826 
info:eu-repo/grantAgreement/FCT/5876/147358/PT 
info:eu-repo/grantAgreement/FCT/SFRH/SFRH/BPD/97650/2013/PT 
info:eu-repo/grantAgreement/FCT/5876/147266/PT 
SFRH/BSAB/127789/2016 
Abstract: Parkinson's Disease (PD) is a long-term neurodegenative brain disorder that mainly affects the motor system. The causes are still unknown, and even though currently there is no cure, several therapeutic options are available to manage its symptoms. The development of novel anti-parkinsonian agents and an understanding of their proper and optimal use are, indeed, highly demanding. For the last decades, L-3,4-DihydrOxyPhenylAlanine or levodopa (L-DOPA) has been the gold-standard therapy for the symptomatic treatment of motor dysfunctions associated to PD. However, the development of dyskinesias and motor fluctuations (wearing-off and on-off phenomena) associated to long-term L-DOPA replacement therapy have limited its antiparkinsonian efficacy. The investigation for non-dopaminergic therapies has been largelyexplored as an attempt to counteract the motor side effects associated to dopamine replacement therapy. Being one of the largest cell membrane protein families, G-Protein-Coupled Receptors (GPCRs) have become a relevant target for drug discovery focused in a wide range of therapeutic areas, including Central Nervous System (CNS) diseases. The modulation of specific GPCRs potentially implicated in PD, excluding dopamine receptors, may provide promising non-dopaminergic therapeutic alternatives for symptomatic treatment of PD. In this review, we focused on the impact of specific GPCR subclasses, including dopamine receptors, adenosine receptors, muscarinic acetylcholine receptors, metabotropic glutamate receptors, and 5-hydroxytryptamine receptors, on the pathophysiology of PD and the importance of structure- and ligand-based in silico approaches for the development of small molecules to target these receptors.
URI: http://hdl.handle.net/10316/48375
DOI: 10.2174/1570159X16666180308161642
Rights: embargoedAccess
Appears in Collections:I&D CNC - Artigos em Revistas Internacionais

Files in This Item:
File Description SizeFormat
CurrNeuro.pdf4.15 MBAdobe PDFView/Open
Show full item record

SCOPUSTM   
Citations

1
checked on Jun 25, 2019

WEB OF SCIENCETM
Citations

1
checked on Jun 25, 2019

Page view(s) 50

352
checked on Aug 14, 2019

Download(s)

86
checked on Aug 14, 2019

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons